These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34454906)

  • 21. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Neutrophil-to-Lymphocyte Ratio and Red Cell Distribution Width With Serum Tumor Markers for the Differential Diagnosis of Breast Cancer and its Association With Pathological Features and Molecular Types.
    Zou H; Liu SH; Yang R; Wu XJ; Cao YP; Huang HF
    Clin Breast Cancer; 2022 Jun; 22(4):e526-e535. PubMed ID: 34963613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers for early breast cancer patients: A retrospective study.
    Fan S; Xie X; Shen Y; Wang W; Gu X; Yao Z
    Medicine (Baltimore); 2022 Aug; 101(32):e30011. PubMed ID: 35960055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
    Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
    J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
    Yang J; Tang A; Ma J; Sun X; Ming L
    Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
    D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
    Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.
    Wen Z; Huang Y; Ling Z; Chen J; Wei X; Su R; Tang Z; Wen Z; Deng Y; Hu Z
    Dis Markers; 2020; 2020():4716793. PubMed ID: 33488842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of serum CA15-3 and CEA in breast cancer.
    Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
    Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
    J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer.
    Pronk LC; Stoter G; van Putten WL; de Wit R
    J Cancer Res Clin Oncol; 1997; 123(2):128-32. PubMed ID: 9030253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukocyte alkaline phosphatase, CA15-3, CA125, and CEA in cancer patients.
    Walach N; Gur Y
    Tumori; 1998; 84(3):360-3. PubMed ID: 9678617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
    Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
    Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients.
    Li X; Dai D; Chen B; Tang H; Xie X; Wei W
    Dis Markers; 2018; 2018():9863092. PubMed ID: 29854028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.
    Robertson JF; Jaeger W; Syzmendera JJ; Selby C; Coleman R; Howell A; Winstanley J; Jonssen PE; Bombardieri E; Sainsbury JR; Gronberg H; Kumpulainen E; Blamey RW
    Eur J Cancer; 1999 Jan; 35(1):47-53. PubMed ID: 10211087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
    Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
    Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.